US Bancorp DE Sells 412 Shares of OrthoPediatrics Corp. (NASDAQ:KIDS)

US Bancorp DE trimmed its position in OrthoPediatrics Corp. (NASDAQ:KIDS) by 15.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,309 shares of the company’s stock after selling 412 shares during the quarter. US Bancorp DE’s holdings in OrthoPediatrics were worth $54,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the company. Quarry LP bought a new position in OrthoPediatrics in the third quarter valued at approximately $25,000. Rhumbline Advisers increased its stake in OrthoPediatrics by 4.1% in the fourth quarter. Rhumbline Advisers now owns 26,411 shares of the company’s stock valued at $612,000 after acquiring an additional 1,042 shares during the last quarter. Quantbot Technologies LP increased its stake in OrthoPediatrics by 42.2% in the third quarter. Quantbot Technologies LP now owns 5,773 shares of the company’s stock valued at $157,000 after acquiring an additional 1,712 shares during the last quarter. BNP Paribas Financial Markets increased its stake in OrthoPediatrics by 125.1% in the third quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company’s stock valued at $94,000 after acquiring an additional 1,929 shares during the last quarter. Finally, R Squared Ltd bought a new position in OrthoPediatrics in the fourth quarter valued at approximately $48,000. 69.05% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Stifel Nicolaus decreased their price objective on shares of OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, March 5th. Truist Financial cut their target price on shares of OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating on the stock in a research report on Wednesday, December 18th. Finally, Needham & Company LLC restated a “buy” rating and issued a $42.00 target price on shares of OrthoPediatrics in a research report on Wednesday, March 5th.

OrthoPediatrics Stock Performance

Shares of OrthoPediatrics stock opened at $25.42 on Wednesday. OrthoPediatrics Corp. has a fifty-two week low of $21.02 and a fifty-two week high of $35.99. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.17 and a quick ratio of 3.68. The firm has a market capitalization of $617.38 million, a P/E ratio of -20.67 and a beta of 1.22. The company’s 50 day moving average price is $24.79 and its two-hundred day moving average price is $25.53.

OrthoPediatrics (NASDAQ:KIDS) last issued its earnings results on Tuesday, March 4th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. The firm had revenue of $52.67 million for the quarter, compared to analyst estimates of $51.16 million. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. During the same quarter last year, the business posted ($0.23) earnings per share. On average, equities analysts forecast that OrthoPediatrics Corp. will post -0.93 earnings per share for the current fiscal year.

Insider Transactions at OrthoPediatrics

In other news, insider Gregory A. Odle sold 5,359 shares of OrthoPediatrics stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $133,224.74. Following the transaction, the insider now owns 148,788 shares in the company, valued at approximately $3,698,869.68. The trade was a 3.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO David R. Bailey sold 6,620 shares of OrthoPediatrics stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $164,573.20. Following the transaction, the chief executive officer now owns 319,155 shares in the company, valued at approximately $7,934,193.30. This trade represents a 2.03 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 23,732 shares of company stock worth $589,978. Company insiders own 31.80% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.